伽玛刀放射外科治疗妇科恶性肿瘤脑转移:病理、生存与肿瘤控制分析
本研究回顾性分析了2008至2020年接受立体定向放射外科(SRS)治疗的妇科脑转移患者。50例患者(宫颈癌4例、子宫内膜癌25例、卵巢癌21例)中,SRS后6个月和12个月总生存率分别为48%和44%,局部肿瘤控制率分别为92%和87%。边缘剂量≥16Gy与显著更好的局部肿瘤控制相关,且未增加不良放射效应风险。
要点
- 妇科脑转移患者SRS后6个月和12个月总生存率分别为48%和44%。
- 边缘剂量≥16Gy与显著更好的局部肿瘤控制相关(p=0.0001)。
- SRS所致不良放射效应事件发生于7例患者。
核心结论
- 妇科恶性肿瘤颅内转移可采用SRS有效治疗,神经毒性风险低。
- 边缘剂量≥16Gy可提供显著更好的肿瘤控制。
- 重复SRS可用于治疗新发转移灶,同时避免全脑放疗(WBRT)相关的潜在认知症状。
研究设计与样本
- 回顾性分析2008年至2020年接受SRS治疗的妇科脑转移患者。
- 共纳入50例患者:宫颈癌4例、子宫内膜癌25例、卵巢癌21例。
- SRS时中位年龄63岁(宫颈癌45.5岁、子宫内膜癌65.5岁、卵巢癌61岁)。
- 中位肿瘤数目3个(范围1-27个),累积肿瘤体积2.33 cc(范围0.03-45.63 cc)。
- 中位边缘处方剂量16 Gy(范围14 Gy-20 Gy),中位12 Gy体积7.30 cc(范围0.21-74.14 cc)。
主要发现
- SRS后6个月和12个月总生存率分别为48%和44%。
- 8例患者(16%)死于中枢神经系统疾病进展。
- 脑转移数目(p=0.011)和卡氏功能状态评分(KPS)≥70(p=0.020)是总生存的显著预测因素。
- 6个月和12个月局部肿瘤控制率分别为92%和87%。
- 边缘剂量≥16Gy与显著更好的局部肿瘤控制相关(p=0.0001),且未增加不良放射效应风险(p=0.055)。
临床怎么用
- 作者认为,妇科恶性肿瘤颅内转移可采用SRS有效治疗,神经毒性风险低。
- 作者认为,边缘剂量≥16Gy可提供显著更好的肿瘤控制。
- 作者认为,重复SRS可用于治疗新发转移灶,同时避免WBRT相关的潜在认知症状。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This study aims to evaluate the efficacy of stereotactic radiosurgery (SRS) in improving health outcomes of patients with gynecologic brain metastases. METHODS: Patients with gynecologic metastases treated with SRS from 2008 to 2020 were retrospectively reviewed. The median age at SRS was 63 years old (cervical 45.5, endometrial 65.5, ovarian 61). The median number of tumors was 3 (range 1-27), and cumulative tumor volume was 2.33 cc (range 0.03-45.63). Median margin dose prescribed was 16 Gy (range 14 Gy - 20 Gy). The median 12 Gy volume was 7.30 cc (range 0.21-74.14 cc). Outcome variables included overall survival (OS) after SRS, local tumor control (LTC), distant tumor control, and adverse radiation effect (ARE). RESULTS: Fifty patients (4 cervical, 25 endometrial, and 21 ovarian cancer) were identified. The OS at 6 and 12 months after SRS was 48%, and 44%, respectively. Eight patients (16%) died from CNS disease progression. The number of brain metastases (p = 0.011) and the Karnofsky Performance Scale (KPS) ≥ 70 (p = 0.020) were significant predictors of OS. LTC rate at 6 and 12 months were 92%, and 87%, respectively. Margin dose ≥16Gy correlated with significantly better local tumor control (p = 0.0001) without increased risk of ARE (p = 0.055). The risk of developing new metastases at 6 and 12 months were 12% and 24% respectively. SRS-induced ARE events occurred in 7 patients. CONCLUSION: Intracranial metastases from gynecologic malignancy can be effectively treated using SRS with low risk of neurotoxicity. Margin dose ≥16Gy can provide significantly better tumor control. Repeat SRS can be utilized to treat new metastases while avoiding the potential cognitive symptoms associated with WBRT.
引用
- Wei Z, Luy DD, Tang LW, et al. Gamma Knife radiosurgery for gynecologic metastases to the brain: Analysis of pathology, survival, and tumor control. Gynecol Oncol. 2023. PMID: 36924726. doi:10.1016/j.ygyno.2023.03.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。